Antithrombotic and antiplatelet therapy in TAVI patients: a fallow field?

被引：13

作者：

Collet, Jean-Philippe ^{[1
]}

Montalescot, Gilles

机构：

[1] Univ Paris 06, F-75013 Paris, France

来源：

EUROINTERVENTION | 2013年 / 9卷

关键词：

antiplatelet agents; bleeding; platelets; stroke; transcatheter aortic valve implantation;

D O I：

10.4244/EIJV9SSA9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Guidelines on antithrombotic therapy after TAVI are scarce and no randomised evaluation has been performed to demonstrate what the best strategy is. Extrapolation from what we know on surgical heart valve replacement is also hazardous as the level of evidence is not very high and the situation, the valves and the patients are different. Patients undergoing TAVI are fragile and at high risk for both bleeding and stroke complications. In addition, the procedure itself may contribute to the occurrence of these complications rendering risk stratification a key step. Improvement in both periprocedural and post-procedural outcome is a major challenge of antithrombotic therapy. The recent release of more potent but also safer antithrombotic therapies is a unique opportunity to sort out what is the best combination for which patient. Our goal is to review the evidence and analyse what are the perspectives in this challenging area.

引用

页码：S43 / S47

页数：5

共 47 条

[1]

Rodes-Cabau J., Dauerman H.L., Cohen M.G., Mehran R., Small E.M., Smyth S.S., Costa M.A., Mega J.L., O'Donoghue M.L., Ohman E.M., Becker R.C., Antithrombotic treatment in transcatheter aortic valve implantation: Insights for cerebrovascular and bleeding events, J Am Coll Cardiol., (2013)

[2]

Whitlock R.P., Sun J.C., Fremes S.E., Rubens F.D., Teoh K.H., Antithrombotic and thrombolytic therapy for valvular disease antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians. Evidence-based clinical practice guidelines, Chest., 141, pp. e576S-e600S, (2012)

[3]

Silvain J., Cayla G., Hulot J.S., Finzi J., Kerneis M., O'Connor S.A., Bellemain-Appaix A., Barthelemy O., Beygui F., Collet J.P., Montalescot G., High on-thienopyridine platelet reactivity in elderly coronary patients: The SENIOR-PLATELET study, Eur Heart J., 33, pp. 1241-1249, (2012)

[4]

Tamburino C., Capodanno D., Ramondo A., Petronio A.S., Ettori F., Santoro G., Klugmann S., Bedogni F., Maisano F., Marzocchi A., Poli A., Antoniucci D., Napodano M., De Carlo M., Fiorina C., Ussia G.P., Incidence and predictors of early and late mortality after transcatheter aortic valve implantation in 663 patients with severe aortic stenosis, Circulation., 123, pp. 299-308, (2011)

[5]

Amat-Santos I.J., Rodes-Cabau J., Urena M., DeLarochelliere R., Doyle D., Bagur R., Villeneuve J., Cote M., Nombela-Franco L., Philippon F., Pibarot P., Dumont E., Incidence, predictive factors, and prognostic value of new-onset atrial fibrillation following transcatheter aortic valve implantation, J Am Coll Cardiol., 59, pp. 178-188, (2012)

[6]

Merie C., Kober L., Skov Olsen P., Andersson C., Gislason G., Skov Jensen J., Torp-Pedersen C., Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding, JAMA., 308, pp. 2118-2125, (2012)

[7]

Stortecky S., Windecker S., Pilgrim T., Heg D., Buellesfeld L., Khattab A.A., Huber C., Gloekler S., Nietlispach F., Mattle H., Juni P., Wenaweser P., Cerebrovascular accidents complicating transcatheter aortic valve implantation: Frequency, timing and impact on outcomes, EuroIntervention., 8, pp. 62-70, (2012)

[8]

Nombela-Franco L., Webb J.G., De Jaegere P.P., Toggweiler S., Nuis R.J., Dager A.E., Amat-Santos I.J., Cheung A., Ye J., Binder R.K., Van Der Boon R.M., Van Mieghem N., Benitez L.M., Perez S., Lopez J., San Roman J.A., Doyle D., Delarochelliere R., Urena M., Leipsic J., Dumont E., Rodes-Cabau J., Timing, predictive factors, and prognostic value of cerebrovascular events in a large cohort of patients undergoing transcatheter aortic valve implantation, Circulation., 126, pp. 3041-3053, (2012)

[9]

Linke A., Gerckens U., Wenaweser P., Tamburino C., Bosmans J., Brecker S., Treatment of high risk aortic stenosis patients with transcatheter Medtronic CoreValve implantation: Results from the international multicenter advance study, J Am Coll Cardiol., 59, (2012)

[10]

Holmes D.R., Mack M.J., Kaul S., Kaul S., Agnihotri A., Alexander K.P., Bailey S.R., Calhoon J.H., Carabello B.A., Desai M.Y., Edwards F.H., Francis G.S., Gardner T.J., Kappetein A.P., Linderbaum J.A., Mukherjee C., Mukherjee D., Otto C.M., Ruiz C.E., Sacco R.L., Smith D., Thomas J.D., Harrington R.A., Bhatt D.L., Ferrari V.A., Fisher J.D., Garcia M.J., Gardner T.J., Gentile F., Gilson M.F., Hernandez A.F., Jacobs A.K., Kaul S., Linderbaum J.A., Moliterno D.J., Weitz H.H., 2012 ACCF/AATS/SCAI/S

← 1 2 3 4 5 →